Sequana Medical Updates on Share Capital and Number of Shares
Sequana Medical NV (Euronext Brussels: SEQUA) is making strides in the field of medical treatment for drug-resistant fluid overload associated with liver disease, heart failure, and cancer. Recently, the company announced significant updates regarding its share capital and the number of shares following the exercise of 30,000 GEM Warrants by GEM Global Yield LLC SCS.
As of July 4, the company’s share capital grew from EUR 5,927,258.66 to EUR 5,930,366.66. This increase was inclusive of the additional 30,000 ordinary shares issued, bringing the total number of issued and outstanding shares to 57,239,575. Each new share was offered at a price of approximately EUR 1.1865.
Outstanding Subscription Rights
Currently, the total number of outstanding subscription rights stands at 7,489,576. These rights, when exercised, allow holders to subscribe to a total of 8,656,304 new shares that come with voting rights. Here’s a detailed breakdown of the different share option plans:
Executive Share Options
The 'Executive Share Options' plan allows for the potential issuance of up to 261,895 new shares through the exercise of 90,780 current share options available to the company’s staff and consultants. This plan is designed to reward those who contribute to the company’s success directly.
2018 and 2021 Share Options
The 2018 Share Options plan permits the issuance of 687,784 shares, while the 2021 plan allows for up to 188,370 new shares through already issued options. Both plans cater to the company's directors, employees, and staff members, incentivizing them to support Sequana Medical's ambitious goals.
2023 and 2025 Share Options
Looking ahead, the 2023 Share Options plan offers the potential to issue 1,000,000 new shares, and the 2025 plan also permits the issuance of another 1,000,000 shares. This strategy aims to strengthen the workforce's investment in the company's long-term performance.
Bootstrap and Kreos Warrants
Additionally, holders of Bootstrap Europe S.C.SP. can exercise rights for up to 302,804 new shares, while Kreos Capital VII Aggregator SCSp. can opt for 1,567,819 shares through their warrants, resulting from approvals from extraordinary shareholders meetings.
Innovation in Treatment Options
Sequana Medical is committed to addressing the challenges posed by fluid overload. With its proprietary platforms, alfapump® and DSR®, the company seeks to provide innovative treatment solutions for patients who experience diuretic resistance—a condition severely affecting their quality of life. By collaborating with healthcare providers, Sequana Medical aims to enhance the efficacy of treatment options available for these patients.
Notably, the company received FDA approval for the alfapump System to treat recurrent ascites due to liver cirrhosis in late 2024. The upcoming commercial launch in the U.S. is set to begin in the third quarter of 2025, targeting the major liver transplant centers throughout the country.
Promising Clinical Results
Encouraging results have been published from the company's RED DESERT and SAHARA studies, demonstrating the effectiveness of DSR in addressing cardiorenal syndrome. Participants in the MOJAVE study have shown a substantial improvement in their diuretic response, significantly reducing their dependency on loop diuretics. Such results affirm the company's commitment to innovation and improving patient outcomes in fluid overload treatment.
Contact Sequana Medical
For more detailed information:
Sequana Medical
Investor relations
E: IR@sequanamedical.com
T: +32 9 292 8065
Frequently Asked Questions
What were the primary outcomes of Sequana Medical's latest share capital announcement?
Sequana Medical's share capital increased slightly due to the exercise of GEM Warrants, bringing its total outstanding shares to 57,239,575.
How does Sequana Medical aim to help patients with fluid overload?
The company offers innovative treatment solutions such as the alfapump® and DSR®, targeting patients who are resistant to diuretics.
What future actions does Sequana Medical plan regarding commercial operations?
Sequana Medical plans to begin U.S. commercialization for its alfapump system in the third quarter of 2025.
What studies support the effectiveness of Sequana Medical's treatments?
Clinical studies, including the RED DESERT and SAHARA studies, have shown positive outcomes for patients treated with DSR therapy.
How can someone get in touch with Sequana Medical for investor relations?
Interested individuals can contact the investor relations team via email at IR@sequanamedical.com.
